loader image

Our Portfolio

Lab-on-a-chip’ technology that delivers oil analysis 1000x faster and 10x cheaper than the current ‘send the sample to laboratory approach.

Eos first invested in:
December 2020

Europes first cancer drug accelerator. Finding assets, creating spin-outs, commercialising cancer therapies.

Eos first invested in:
June 2020

Utilises the power of natural silver across a wide range of everyday products by transforming them into permanent antimicrobial materials.

Eos first invested in:
February 2020

Formed in 2014 to offer Adjusta-Cone® as the world’s first fully adjustable differential pressure cone meter for natural gas.

Eos first invested in:
January 2020

Connects seafood buyers and suppliers, giving them the right tools to trade efficiently, negotiate prices and process deliveries across Europe – all in real-time, 24/7.

Eos first invested in:
October 2019

Offers a revolutionary spectroscopic liquid biopsy with artificial intelligence for the early detection of cancer and other diseases.

Eos first invested in:
February 2019

An award winning Scottish sensors company utilising thin-film processes to eliminate conventional limitations in ultrasound sensors.

Eos first invested in:
April 2018

ABUNDA mycoprotein is a fermented food ingredient, rich in protein and fibre. Naturally fortified in B12, zinc and iron. ABUNDA is highly nutritious. The fibrous nature of the product gives an outstanding meaty texture, naturally.

Eos first invested in:
June 2017

A provider of specialist genetics and breeding management services to the aquaculture industry.

Eos first invested in:
March 2016

With minimal set-up and an intuitive web browser interface, their femtosecond lasers and picosecond OPOs, enable the scientific community and industrial partners to push boundaries and discover more.

Eos first invested in:
December 2015

AI and Content Automation to help companies achieve incredible marketing results through Digital Video.

Eos first invested in:
December 2015

An early stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for Virology, Cancer, Atopic Dermatitis and Psoriasis.

Eos first invested in:
July 2015

Player vs Player (PvP) football management mobile game made by a BAFTA award winning team of game industry executives.

Eos first invested in:
January 2015

logo
Registered in Scotland.
Company Number: SO306577
Eos Advisory LLP is an Appointed Representative of Javelin Ventures Limited (FCA Ref:207918), which is authorised and regulated by the Financial Conduct Authority

Discover

Links

Contact

Eos Advisory LLP,
Kinburn Castle,
Doubledykes Road,
St Andrews, KY16 9DR

Envelope
Linkedin-in

Copyright © 2021 Eos Advisory LLP | All rights reserved

Latest news

ALL NEWS
Envelope
Linkedin-in
ALL NEWS

This website uses cookies to ensure you get the best experience on our website. By continuing to browse on this website, you accept the use of cookies for the above purposes.

I Understand

Ben Hasselgren

Information Technology & Design

Valerie Jolliffe

Investment Committee & Fund Manager

Valerie founded Javelin Ventures Limited in 2001 currently also manages EIS funds for Newable (London) and Halo Business Angels (Belfast.) Valerie also acts as head of finance for one of the Iceni spin-outs. Valerie has a degree in engineering from Cambridge University, a masters in charity finance and accounting from Cass Business School, and is a Chartered Secretary.

Calum Keddie

Investment Executive

Calum Keddie is an early stage investment professional with experience in the investment and banking industries. Prior to joining Eos-Advisory, Calum worked at the early stage investment firm, Two Magnolias, and was responsible for sourcing, screening and transacting venture capital deals in the impact investment sector. He has also had roles at Rolls-Royce Plc. aerospace division and at ING Bank in the market risk function for structured products. Calum is an MBA candidate at Warwick Business School and earned his undergraduate degree in Finance from the University of Strathclyde. He has previously been selected to represent the British Council in India and China and has lived in Canada, Norway and Singapore.

profile

Chris Brinsmead CBE

Eos Advisory Partner

Chris Brinsmead is a council member at Imperial College London, a former adviser to the UK Government on life sciences, has previously held senior executive roles at ICI, Zeneca and AstraZeneca, and over the last decade has been a non-executive board member and chair on a number of private and public limited company boards. And from 2010 until 2017 he was an independent Advisor to the Prime Minister and other senior government ministers on Life Sciences 2010.

profile

Ana Stewart

Eos Advisory Partner

Ana founded her digital consultancy business after graduating from University and grew it into a leading global innovator consumer engagement software. As CEO, she led the AIM listing of the company on the London Stock Exchange and was voted Emerging Entrepreneur of the Year by the Scottish Entrepreneurial Exchange. Ana sold then sold the company in a US trade sale. Ana sits on the Board of the Scottish FA and also sits on the main council of ICAS.

profile

Rick Clark

Eos Advisory Partner

Rick is the CFO of a private equity-funded business in the energy sector and is a NXD of two other companies. He is also on the board of a charity which owns and operates 2 nationally-significant museums and is a member of the ICAS Ethics Board. His prior experience in the energy sector was with a technology-led oilfield services company which he helped build rapidly prior to its successful sale. Before that he was a partner with KPMG for 15 years.

profile

Mark Beaumont BEM

Eos Advisory Partner

Mark Beaumont spent the first 15 years of his career building teams around sporting success and is best known as an athlete and BBC broadcaster. He still holds the 18,000-mile circumnavigation cycling record in a time of 78 days along. Mark’s degree education was in Economics & Politics, and for over thirteen years he has also worked with LDC, the UK’s leading mid-market private equity firm, in their deal origination team.

profile

Andrew McNeill Phd

Eos Advisory Managing Partner

Andrew McNeill has over 15 years’ experience in leading early stage venture capital backed medical device and biotech companies. Andrew holds a PhD in Molecular Physics from Leeds University. He was part of the founding team at Ambicare Health, a medical device company in the oncology space and took several technologies from lab through to market. Subsequent to that he was CEO of biotechnology company Fixed Phage before joining Eos in 2017.

profile

Kevin Grainger

Eos Advisory Chairman

Kevin Grainger is a serial entrepreneur with over 35 years track record in the IT and investment sectors. Having worked in both corporate and SME/start-up environments, Kevin has a wealth of business experience and a university education in physics that lead to a passion for seeing innovative technologies and science being successfully commercialised. Kevin founded the Eos in 2014.

Who are you?

I am interested in joining the Syndicate
I am interested in EIS Fund investing
I am looking for co-investment opportunities
I am seeking investment

Syndicate Application Form

Please ensure that all the information entered is correct.